Skip to main content
. 2020 Sep;8(18):1176. doi: 10.21037/atm-20-5952

Figure 2.

Figure 2

Kaplan-Meier survival analysis of patients with or without signature 4. (A) Patients with LUAD; (B) patients with LUSC. The red line shows patients with signature 4; Blue line indicates patients without signature 4. Ticks, censoring events. P value, log-rank analysis. The follow-up is cut at 60 months. HR, hazard ratio; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.